Inovio Pharmaceuticals Total Liabilities

As of the most recent data (March 2026), INO shows a total liabilities of $44B. That compares with $36B in the prior-year period — up 21.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INO's total liabilities is now $44B (was $36B) — a 21.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Inovio Pharmaceuticals is outperforming or lagging.

Tracking INO's total liabilities over time shows whether Inovio Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $44B That compares with $36B in the prior-year period — up 21.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Inovio Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $44B) with ownership activity and broader fundamentals.

Inovio Pharmaceuticals's total liabilities is $44B; compare it with other Industrials names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.